Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy

Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy

[...]the identification of biomarkers and prognostic models to select patients for these combination therapies is a crucial issue in clinical practice. Compared to historical Meet-URO-related studies (Additional file 1), this small-size analysis explored the prognostic value of the Meet-URO score in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of translational medicine 2024-03, Vol.22 (1), p.232-4, Article 232
Hauptverfasser: He, Sike, Liu, Haoyang, Chen, Junru, Zeng, Hao
Format: Artikel
Sprache:eng
Schlagworte:
Carcinoma, Renal Cell - drug therapy
Clear cell-type renal cell carcinoma
Clinical medicine
Consortia
Humans
Immune Checkpoint Inhibitors
Immunotherapy
Kidney cancer
Letter to the Editor
Medical prognosis
Metastases
Metastasis
Nephrectomy
Neutrophils
Patients
Tyrosine Kinase Inhibitors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:[...]the identification of biomarkers and prognostic models to select patients for these combination therapies is a crucial issue in clinical practice. Compared to historical Meet-URO-related studies (Additional file 1), this small-size analysis explored the prognostic value of the Meet-URO score in similar disease status but with a different treatment type. [...]the results about the positive effect of nephrectomy are consistent with a subgroup analysis of the Meet-URO 15 study (HR = 0.48, 95% CI 0.33 to 0.69, p 
ISSN:1479-5876
1479-5876
DOI:10.1186/s12967-024-05014-z